Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 10 years
- Director since
- 2023
10 years of board service in total across 3 boards, counting each seat separately. Longest: Allogene Therapeutics Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
UroGen Pharma Ltd. June 22, 202682.5%
-
UroGen Pharma Ltd. August 26, 202591.0%
-
Allogene Therapeutics Inc. June 18, 202595.9%
-
Ginkgo Bioworks Holdings Inc. June 16, 202398.6%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 24, 2025 | Allogene Therapeutics Inc. | Grant or award | +369,957 | — | — |
| Jun 12, 2024 | Ginkgo Bioworks Holdings Inc. | Option exercise | +105,263 | — | — |
| May 16, 2024 | Allogene Therapeutics Inc. | Grant or award | +344,828 | $2.90 | $1,000,001 |
| May 16, 2024 | Allogene Therapeutics Inc. | Open-market purchase | +1,724,137 | $2.90 | $4,999,997 |
| Jan 25, 2024 | Allogene Therapeutics Inc. | Grant or award | +211,973 | — | — |
| Mar 22, 2023 | Allogene Therapeutics Inc. | Grant or award | +1,282,976 | — | — |
Questions about Arie Belldegrun
What boards is Arie Belldegrun on?
Arie Belldegrun sits on the boards of Allogene Therapeutics Inc., Ginkgo Bioworks Holdings Inc. and UroGen Pharma Ltd.
How long has Arie Belldegrun served on boards?
Our records show at least 10 years of board service across 3 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.